Skip to main content

Acute Myeloid Leukemia

Dr Jamy
Videos
01/18/2022
Omer Hassan Jamy, MD, highlights a retrospective study on HMAs plus venetoclax versus intensive chemotherapy for patients with R/R AML. These data were presented at the 2021 ASH Annual Meeting.
Omer Hassan Jamy, MD, highlights a retrospective study on HMAs plus venetoclax versus intensive chemotherapy for patients with R/R AML. These data were presented at the 2021 ASH Annual Meeting.
Omer Hassan Jamy, MD, highlights...
01/18/2022
Oncology
Musa Yilmaz, MD
Videos
11/03/2021
Musa Yilmaz, MD, discusses a highly active triplet combination for patients with FLT3-ITD mutated AML. These data were presented at the 2021 ASCO Annual Meeting.
Musa Yilmaz, MD, discusses a highly active triplet combination for patients with FLT3-ITD mutated AML. These data were presented at the 2021 ASCO Annual Meeting.
Musa Yilmaz, MD, discusses a...
11/03/2021
Oncology
Mark Levis, MD, PhD
Videos
06/05/2021
Dr Levis discusses a study examining FF-10101-01, an irreversible FLT3 inhibitor, in patients with relapsed/refractory AML, which was presented at the 2021 ASCO Annual Meeting.
Dr Levis discusses a study examining FF-10101-01, an irreversible FLT3 inhibitor, in patients with relapsed/refractory AML, which was presented at the 2021 ASCO Annual Meeting.
Dr Levis discusses a study...
06/05/2021
Oncology
Gail Roboz, MD, Hints at Topics in AML, ALL Being Debated and Addressed
Videos
06/14/2020
Dr Roboz gives attendees a taste of what's to come at this year's virtual Great Debates & Updates in Hematologic Malignancies.
Dr Roboz gives attendees a taste of what's to come at this year's virtual Great Debates & Updates in Hematologic Malignancies.
Dr Roboz gives attendees a taste...
06/14/2020
Oncology